Keiko Maekawa
- Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism 23
- Drug-Induced Adverse Reactions 7
-
- Neuropeptides and Animal Physiology 6
- Biochemistry top 2%
- Eicosanoids and Hypertension Pharmacology 6
- Oncology top 5%
- Drug Transport and Resistance Mechanisms 17
- Physiology top 5%
-
- Metabolomics and Mass Spectrometry Studies 9
- Receptor Mechanisms and Signaling 7
-
- Liver Disease Diagnosis and Treatment 7
- Co-authors
- Yoshiro SaitoMasabumi MinamiMasaki IshikawaKosuke SaitoKazuki YabuuchiJun‐ichi SawadaTakashi ToyaTatsuhiro Onogi
- Journals
- Journal of Clinical Oncology (1 paper)SHILAP Revista de lepidopterología (1 paper)PLoS ONE (4 papers)
- Partner nations
- JapanUnited StatesUnited Kingdom
In The Last Decade
Keiko Maekawa
93 papers receiving 2.8k citations
Peers
Comparison fields: 5 of 121
- Pharmacology 625
- Cellular and Molecular Neuroscience 542
- Biochemistry 198
- Oncology 665
- Physiology 529
Countries citing papers authored by Keiko Maekawa
This map shows the geographic impact of Keiko Maekawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keiko Maekawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keiko Maekawa more than expected).
Fields of papers citing papers by Keiko Maekawa
This network shows the impact of papers produced by Keiko Maekawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keiko Maekawa. The network helps show where Keiko Maekawa may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Keiko Maekawa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2022 | 5 | |
| 3 | 2022 | 26 | |
| 4 | 2019 | 18 | |
| 5 | 2017 | 1 | |
| 6 | 2014 | 155 | |
| 7 | 2013 | 116 | |
| 8 | 2013 | 33 | |
| 9 | [Trends in drug-induced liver injury based on reports of adverse reactions to PMDA in Japan]. | 2012 | 2 |
| 10 | 2009 | 49 | |
| 11 | 2007 | 52 | |
| 12 | 2007 | 13 | |
| 13 | 2005 | 19 | |
| 14 | 2004 | 9 | |
| 15 | 2003 | 23 | |
| 16 | 2001 | 4 | |
| 17 | 1996 | 54 | |
| 18 | 1993 | 38 | |
| 19 | 1993 | 198 | |
| 20 | 1982 | 2 |
About Keiko Maekawa
Keiko Maekawa is a scholar working on Pharmacology, Biochemistry and Oncology, having authored 98 papers that have together received 2.8k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (23 papers), Drug Transport and Resistance Mechanisms (17 papers), Metabolomics and Mass Spectrometry Studies (9 papers), Receptor Mechanisms and Signaling (7 papers), Drug-Induced Adverse Reactions (7 papers), Liver Disease Diagnosis and Treatment (7 papers), Eicosanoids and Hypertension Pharmacology (6 papers) and Neuropeptides and Animal Physiology (6 papers). The work is most often cited by research in Pharmacology (625 citations), Cellular and Molecular Neuroscience (542 citations) and Biochemistry (198 citations). Keiko Maekawa has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yoshiro Saito, Masabumi Minami, Masaki Ishikawa, Kosuke Saito, Kazuki Yabuuchi, Jun‐ichi Sawada, Takashi Toya, Tatsuhiro Onogi, Yoshikazu Katao and Yuya Senoo. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.